{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:48:04Z","timestamp":1790887684035,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM114179"],"award-info":[{"award-number":["GM114179"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10928-020-09713-0","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T10:02:59Z","timestamp":1599040979000},"page":"597-612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits"],"prefix":"10.1007","volume":"47","author":[{"given":"David","family":"Bussing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0723-6206","authenticated-orcid":false,"given":"Dhaval","family":"K. Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"key":"9713_CR1","unstructured":"Gordois A, Pezzullo L, Cutler H (2010) The Global Economic Cost of Visual Impairment. Access Economics Pty Limited for AMD Alliance International"},{"issue":"2","key":"9713_CR2","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2(2):e106\u2013116. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1","journal-title":"Lancet Glob Health"},{"key":"9713_CR3","unstructured":"Global $10.4 Bn Wet Age-Related Macular Degeneration Market to 2024\u2014 Rising Prevalence of AMD, Lack of a Specific Treatment, and Increasing Aging Population (2019). GlobeNewswire, 2019\/05\/15"},{"issue":"9","key":"9713_CR4","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1021\/acs.molpharmaceut.5b00849","volume":"13","author":"LA Hutton-Smith","year":"2016","unstructured":"Hutton-Smith LA, Gaffney EA, Byrne HM, Maini PK, Schwab D, Mazer NA (2016) A Mechanistic model of the intravitreal pharmacokinetics of large molecules and the pharmacodynamic suppression of ocular vascular endothelial growth factor levels by ranibizumab in patients with neovascular age-related macular degeneration. Mol Pharm 13(9):2941\u20132950. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00849","journal-title":"Mol Pharm"},{"issue":"8","key":"9713_CR5","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1021\/acs.molpharmaceut.7b00164","volume":"14","author":"LA Hutton-Smith","year":"2017","unstructured":"Hutton-Smith LA, Gaffney EA, Byrne HM, Maini PK, Gadkar K, Mazer NA (2017) Ocular pharmacokinetics of therapeutic antibodies given by intravitreal injection: estimation of retinal permeabilities using a 3-compartment semi-mechanistic model. Mol Pharm 14(8):2690\u20132696. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00164","journal-title":"Mol Pharm"},{"issue":"6","key":"9713_CR6","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1167\/iovs.16-19204","volume":"57","author":"SJ Park","year":"2016","unstructured":"Park SJ, Choi Y, Na YM, Hong HK, Park JY, Park KH, Chung JY, Woo SJ (2016) Intraocular pharmacokinetics of intravitreal aflibercept (Eylea) in a rabbit model. Invest Ophthalmol Vis Sci 57(6):2612\u20132617. https:\/\/doi.org\/10.1167\/iovs.16-19204","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"9713_CR7","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1177\/019262339902700507","volume":"27","author":"J Mordenti","year":"1999","unstructured":"Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, Allen PC, Valverde CR, Meng YG, Fei DT, Fourre KM, Ryan AM (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27(5):536\u2013544. https:\/\/doi.org\/10.1177\/019262339902700507","journal-title":"Toxicol Pathol"},{"issue":"5","key":"9713_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.survophthal.2014.02.004","volume":"59","author":"WJ Kheir","year":"2014","unstructured":"Kheir WJ, Sniegowski MC, El-Sawy T, Li A, Esmaeli B (2014) Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy. Surv Ophthalmol 59(5):493\u2013502. https:\/\/doi.org\/10.1016\/j.survophthal.2014.02.004","journal-title":"Surv Ophthalmol"},{"issue":"26","key":"9713_CR9","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1200\/JCO.2011.41.5851","volume":"30","author":"DJ Renouf","year":"2012","unstructured":"Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL (2012) Ocular toxicity of targeted therapies. J Clin Oncol 30(26):3277\u20133286. https:\/\/doi.org\/10.1200\/JCO.2011.41.5851","journal-title":"J Clin Oncol"},{"key":"9713_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/OTT.S54606","volume":"7","author":"T Hager","year":"2013","unstructured":"Hager T, Seitz B (2013) Ocular side effects of biological agents in oncology: what should the clinician be aware of? Onco Targets Ther 7:69\u201377. https:\/\/doi.org\/10.2147\/OTT.S54606","journal-title":"Onco Targets Ther"},{"issue":"10","key":"9713_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","volume":"31","author":"JS Eaton","year":"2015","unstructured":"Eaton JS, Miller PE, Mannis MJ, Murphy CJ (2015) Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther 31(10):589\u2013604. https:\/\/doi.org\/10.1089\/jop.2015.0064","journal-title":"J Ocul Pharmacol Ther"},{"issue":"8","key":"9713_CR12","first-page":"3969","volume":"46","author":"DG Covell","year":"1986","unstructured":"Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN (1986) Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. Cancer Res 46(8):3969\u20133978","journal-title":"Cancer Res"},{"issue":"6","key":"9713_CR13","first-page":"1517","volume":"54","author":"LT Baxter","year":"1994","unstructured":"Baxter LT, Zhu H, Mackensen DG, Jain RK (1994) Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54(6):1517\u20131528","journal-title":"Cancer Res"},{"issue":"11","key":"9713_CR14","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1007\/s10439-005-7410-3","volume":"33","author":"GZ Ferl","year":"2005","unstructured":"Ferl GZ, Wu AM, DiStefano JJ 3rd (2005) A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng 33(11):1640\u20131652. https:\/\/doi.org\/10.1007\/s10439-005-7410-3","journal-title":"Ann Biomed Eng"},{"issue":"5","key":"9713_CR15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s10928-007-9065-1","volume":"34","author":"A Garg","year":"2007","unstructured":"Garg A, Balthasar JP (2007) Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34(5):687\u2013709. https:\/\/doi.org\/10.1007\/s10928-007-9065-1","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"9713_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","volume":"39","author":"DK Shah","year":"2012","unstructured":"Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39(1):67\u201386. https:\/\/doi.org\/10.1007\/s10928-011-9232-2","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9713_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.exer.2015.05.003","volume":"137","author":"EM del Amo","year":"2015","unstructured":"del Amo EM, Urtti A (2015) Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data. Exp Eye Res 137:111\u2013124. https:\/\/doi.org\/10.1016\/j.exer.2015.05.003","journal-title":"Exp Eye Res"},{"issue":"1","key":"9713_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0192623307310955","volume":"36","author":"BG Short","year":"2008","unstructured":"Short BG (2008) Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol Pathol 36(1):49\u201362. https:\/\/doi.org\/10.1177\/0192623307310955","journal-title":"Toxicol Pathol"},{"issue":"1","key":"9713_CR19","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1006\/taap.1996.0284","volume":"141","author":"S Pepin-Covatta","year":"1996","unstructured":"Pepin-Covatta S, Lutsch C, Grandgeorge M, Lang J, Scherrmann JM (1996) Immunoreactivity and pharmacokinetics of horse anti-scorpion venom F(ab')2-scorpion venom interactions. Toxicol Appl Pharmacol 141(1):272\u2013277. https:\/\/doi.org\/10.1006\/taap.1996.0284","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"9713_CR20","first-page":"1","volume":"281","author":"G Riviere","year":"1997","unstructured":"Riviere G, Choumet V, Audebert F, Sabouraud A, Debray M, Scherrmann JM, Bon C (1997) Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: toward an optimization of antivenom therapy. J Pharmacol Exp Ther 281(1):1\u20138","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"9713_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/s0041-0101(97)00062-7","volume":"36","author":"M Ismail","year":"1998","unstructured":"Ismail M, Abd-Elsalam MA, Al-Ahaidib MS (1998) Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its distribution of the venom and its toxin versus slow absorption and distribution of IGG, F(AB')2 and F(AB) of the antivenin. Toxicon 36(1):93\u2013114. https:\/\/doi.org\/10.1016\/s0041-0101(97)00062-7","journal-title":"Toxicon"},{"issue":"8","key":"9713_CR22","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2165\/00003088-200342080-00002","volume":"42","author":"JM Gutierrez","year":"2003","unstructured":"Gutierrez JM, Leon G, Lomonte B (2003) Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation. Clin Pharmacokinet 42(8):721\u2013741. https:\/\/doi.org\/10.2165\/00003088-200342080-00002","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"9713_CR23","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.1128\/AAC.00460-13","volume":"57","author":"NV Malkevich","year":"2013","unstructured":"Malkevich NV, Basu S, Rudge TL Jr, Clement KH, Chakrabarti AC, Aimes RT, Nabors GS, Skiadopoulos MH, Ionin B (2013) Effect of anthrax immune globulin on response to BioThrax (anthrax vaccine adsorbed) in New Zealand white rabbits. Antimicrob Agents Chemother 57(11):5693\u20135696. https:\/\/doi.org\/10.1128\/AAC.00460-13","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"9713_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/cts.12433","volume":"10","author":"CF Nagy","year":"2017","unstructured":"Nagy CF, Mondick J, Serbina N, Casey LS, Carpenter SE, French J, Guttendorf R (2017) Animal-to-human dose translation of obiltoxaximab for treatment of inhalational anthrax under the US FDA animal rule. Clin Transl Sci 10(1):12\u201319. https:\/\/doi.org\/10.1111\/cts.12433","journal-title":"Clin Transl Sci"},{"issue":"5","key":"9713_CR25","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114(5):855\u2013859. https:\/\/doi.org\/10.1016\/j.ophtha.2007.01.017","journal-title":"Ophthalmology"},{"issue":"10","key":"9713_CR26","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1167\/iovs.08-3148","volume":"50","author":"H Nomoto","year":"2009","unstructured":"Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K, Nugent AK, Hirooka K, Baba T (2009) Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 50(10):4807\u20134813. https:\/\/doi.org\/10.1167\/iovs.08-3148","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9713_CR27","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2147\/OPTH.S19555","volume":"5","author":"CI Sinapis","year":"2011","unstructured":"Sinapis CI, Routsias JG, Sinapis AI, Sinapis DI, Agrogiannis GD, Pantopoulou A, Theocharis SE, Baltatzis S, Patsouris E, Perrea D (2011) Pharmacokinetics of intravitreal bevacizumab (Avastin(R)) in rabbits. Clin Ophthalmol 5:697\u2013704. https:\/\/doi.org\/10.2147\/OPTH.S19555","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"9713_CR28","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1167\/iovs.15-17108","volume":"56","author":"K Gadkar","year":"2015","unstructured":"Gadkar K, Pastuskovas CV, Le Couter JE, Elliott JM, Zhang J, Lee CV, Sanowar S, Fuh G, Kim HS, Lombana TN, Spiess C, Nakamura M, Hass P, Shatz W, Meng YG, Scheer JM (2015) Design and pharmacokinetic characterization of novel antibody formats for ocular therapeutics. Invest Ophthalmol Vis Sci 56(9):5390\u20135400. https:\/\/doi.org\/10.1167\/iovs.15-17108","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"9713_CR29","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/0002-9378(85)90165-6","volume":"151","author":"RL Johnson","year":"1985","unstructured":"Johnson RL, Gilbert M, Meschia G, Battaglia FC (1985) Cardiac output distribution and uteroplacental blood flow in the pregnant rabbit: a comparative study. Am J Obstet Gynecol 151(5):682\u2013686. https:\/\/doi.org\/10.1016\/0002-9378(85)90165-6","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"9713_CR30","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1023\/a:1018943613122","volume":"10","author":"B Davies","year":"1993","unstructured":"Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10(7):1093\u20131095. https:\/\/doi.org\/10.1023\/a:1018943613122","journal-title":"Pharm Res"},{"issue":"10","key":"9713_CR31","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/jps.2600721003","volume":"72","author":"LE Gerlowski","year":"1983","unstructured":"Gerlowski LE, Jain RK (1983) Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci 72(10):1103\u20131127. https:\/\/doi.org\/10.1002\/jps.2600721003","journal-title":"J Pharm Sci"},{"issue":"6","key":"9713_CR32","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1080\/08958370802601569","volume":"21","author":"LM Sweeney","year":"2009","unstructured":"Sweeney LM, Kirman CR, Gannon SA, Thrall KD, Gargas ML, Kinzell JH (2009) Development of a physiologically based pharmacokinetic (PBPK) model for methyl iodide in rats, rabbits, and humans. Inhal Toxicol 21(6):552\u2013582. https:\/\/doi.org\/10.1080\/08958370802601569","journal-title":"Inhal Toxicol"},{"issue":"1\u20132","key":"9713_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(01)00150-8","volume":"50","author":"MA Swartz","year":"2001","unstructured":"Swartz MA (2001) The physiology of the lymphatic system. Adv Drug Deliv Rev 50(1\u20132):3\u201320","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"9713_CR34","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/jps.21918","volume":"99","author":"SR Urva","year":"2010","unstructured":"Urva SR, Yang VC, Balthasar JP (2010) Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci 99(3):1582\u20131600. https:\/\/doi.org\/10.1002\/jps.21918","journal-title":"J Pharm Sci"},{"key":"9713_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/2040-2384-2-14","volume":"2","author":"H Sarin","year":"2010","unstructured":"Sarin H (2010) Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res 2:14. https:\/\/doi.org\/10.1186\/2040-2384-2-14","journal-title":"J Angiogenes Res"},{"issue":"9","key":"9713_CR36","doi-asserted-by":"publisher","first-page":"e0185662","DOI":"10.1371\/journal.pone.0185662","volume":"12","author":"B Szikora","year":"2017","unstructured":"Szikora B, Hiripi L, Bender B, Kacskovics I, Ilias A (2017) Characterization of the interactions of rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG isotypes. PLoS ONE 12(9):e0185662. https:\/\/doi.org\/10.1371\/journal.pone.0185662","journal-title":"PLoS ONE"},{"issue":"3","key":"9713_CR37","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10928-019-09639-2","volume":"46","author":"Z Li","year":"2019","unstructured":"Li Z, Shah DK (2019) Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics. J Pharmacokinet Pharmacodyn 46(3):305\u2013318. https:\/\/doi.org\/10.1007\/s10928-019-09639-2","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9713_CR38","volume-title":"ADAPT 5 user's guide: pharmacokinetic\/pharmacodynamic systems analysis software","author":"DZ D'Argenio","year":"2009","unstructured":"D'Argenio DZ, Schumitzky A, Wang X (2009) ADAPT 5 user's guide: pharmacokinetic\/pharmacodynamic systems analysis software. Biomedical Simiulations Resource, Los Angeles"},{"key":"9713_CR39","volume-title":"Berkeley Madonna user's guide","author":"R Macey","year":"2009","unstructured":"Macey R, Oster G, Zahnley T (2009) Berkeley Madonna user's guide. University of California, Berkeley"},{"issue":"6","key":"9713_CR40","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/0969-8051(95)00008-l","volume":"22","author":"M Chakrabarti","year":"1995","unstructured":"Chakrabarti M, Cheng KT, Spicer KM, Kirsch WM, Fowler SD, Kelln W, Griende S, Nehlsen-Cannarella S, Willerson R, Spicer SS et al (1995) Biodistribution and radioimmunopharmacokinetics of 131I-Ama monoclonal antibody in atherosclerotic rabbits. Nucl Med Biol 22(6):693\u2013697. https:\/\/doi.org\/10.1016\/0969-8051(95)00008-l","journal-title":"Nucl Med Biol"},{"issue":"1","key":"9713_CR41","first-page":"371","volume":"288","author":"YS Lin","year":"1999","unstructured":"Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB (1999) Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288(1):371\u2013378","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"9713_CR42","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1748-1716.1987.tb08257.x","volume":"131","author":"B Rippe","year":"1987","unstructured":"Rippe B, Haraldsson B (1987) Fluid and protein fluxes across small and large pores in the microvasculature. Application of two-pore equations. Acta Physiol Scand 131(3):411\u2013428. https:\/\/doi.org\/10.1111\/j.1748-1716.1987.tb08257.x","journal-title":"Acta Physiol Scand"},{"issue":"1","key":"9713_CR43","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1152\/physrev.1994.74.1.163","volume":"74","author":"B Rippe","year":"1994","unstructured":"Rippe B, Haraldsson B (1994) Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev 74(1):163\u2013219. https:\/\/doi.org\/10.1152\/physrev.1994.74.1.163","journal-title":"Physiol Rev"},{"issue":"23","key":"9713_CR44","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1002\/cncr.27622","volume":"118","author":"M Beeram","year":"2012","unstructured":"Beeram M, Krop IE, Burris HA, Girish SR, Yu W, Lu MW, Holden SN, Modi S (2012) A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer 118(23):5733\u20135740. https:\/\/doi.org\/10.1002\/cncr.27622","journal-title":"Cancer"},{"issue":"4","key":"9713_CR45","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","volume":"29","author":"HA Burris 3rd","year":"2011","unstructured":"Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29(4):398\u2013405. https:\/\/doi.org\/10.1200\/JCO.2010.29.5865","journal-title":"J Clin Oncol"},{"issue":"4","key":"9713_CR46","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/01.cji.0000208259.73167.58","volume":"29","author":"AV Maker","year":"2006","unstructured":"Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, Allen T, Mavroukakis SA, Attia P, Rosenberg SA (2006) Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 29(4):455\u2013463. https:\/\/doi.org\/10.1097\/01.cji.0000208259.73167.58","journal-title":"J Immunother"},{"issue":"4","key":"9713_CR47","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00520-012-1645-y","volume":"21","author":"DS Borkar","year":"2013","unstructured":"Borkar DS, Lacouture ME, Basti S (2013) Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer 21(4):1167\u20131174. https:\/\/doi.org\/10.1007\/s00520-012-1645-y","journal-title":"Support Care Cancer"},{"issue":"3","key":"9713_CR48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3109\/15569527.2011.636118","volume":"31","author":"FT Fraunfelder","year":"2012","unstructured":"Fraunfelder FT, Fraunfelder FW (2012) Trichomegaly and other external eye side effects associated with epidermal growth factor. Cutan Ocul Toxicol 31(3):195\u2013197. https:\/\/doi.org\/10.3109\/15569527.2011.636118","journal-title":"Cutan Ocul Toxicol"},{"key":"9713_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2014.S005.x","author":"C Struble","year":"2014","unstructured":"Struble C, Howard S, Relph J (2014) Comparison of ocular tissue weights (volumes) and tissue collection techniques in commonly used preclinical animal species. Acta Ophthalmol. https:\/\/doi.org\/10.1111\/j.1755-3768.2014.S005.x","journal-title":"Acta Ophthalmol"},{"key":"9713_CR50","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","volume":"57","author":"EM del Amo","year":"2017","unstructured":"del Amo EM, Rimpel\u00e4 A-K, Heikkinen E, Kari OK, Ramsay E, Lajunen T, Schmitt M, Pelkonen L, Bhattacharya M, Richardson D, Subrizi A, Turunen T, Reinisalo M, Itkonen J, Toropainen E, Casteleijn M, Kidron H, Antopolsky M, Vellonen K-S, Ruponen M, Urtti A (2017) Pharmacokinetic aspects of retinal drug delivery. Progress in Retinal and Eye Research 57:134\u2013185. https:\/\/doi.org\/10.1016\/j.preteyeres.2016.12.001","journal-title":"Progress in Retinal and Eye Research"},{"key":"9713_CR51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-3-540-69469-4_2","volume-title":"Ocular blood flow","author":"SFE Nilsson","year":"2012","unstructured":"Nilsson SFE, Alm A (2012) Determination of ocular blood flows with the microsphere method. In: Schmetterer L, Kiel J (eds) Ocular blood flow. Springer, Berlin, pp 25\u201347. https:\/\/doi.org\/10.1007\/978-3-540-69469-4_2"},{"issue":"2","key":"9713_CR52","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/s0014-4835(70)80035-5","volume":"10","author":"I Fatt","year":"1970","unstructured":"Fatt I, Hedbys BO (1970) Flow of water in the sclera. Exp Eye Res 10(2):243\u2013249. https:\/\/doi.org\/10.1016\/s0014-4835(70)80035-5","journal-title":"Exp Eye Res"},{"issue":"1 Pt 2","key":"9713_CR53","doi-asserted-by":"publisher","first-page":"F104","DOI":"10.1152\/ajprenal.1987.252.1.F104","volume":"252","author":"DM Maurice","year":"1987","unstructured":"Maurice DM (1987) Flow of water between aqueous and vitreous compartments in the rabbit eye. Am J Physiol 252(1 Pt 2):F104\u2013108. https:\/\/doi.org\/10.1152\/ajprenal.1987.252.1.F104","journal-title":"Am J Physiol"},{"issue":"12","key":"9713_CR54","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1021\/js9802594","volume":"87","author":"MR Prausnitz","year":"1998","unstructured":"Prausnitz MR, Noonan JS (1998) Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci 87(12):1479\u20131488","journal-title":"J Pharm Sci"},{"key":"9713_CR55","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ajo.2016.05.005","volume":"168","author":"Q Wang","year":"2016","unstructured":"Wang Q, Chan S, Yang JY, You B, Wang YX, Jonas JB, Wei WB (2016) Vascular density in retina and choriocapillaris as measured by optical coherence tomography angiography. Am J Ophthalmol 168:95\u2013109. https:\/\/doi.org\/10.1016\/j.ajo.2016.05.005","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"9713_CR56","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1113\/jphysiol.1966.sp007912","volume":"184","author":"A Ames 3rd","year":"1966","unstructured":"Ames A 3rd, Nesbett FB (1966) Intracellular and extracellular compartments of mammalian central nervous tissue. J Physiol 184(1):215\u2013238. https:\/\/doi.org\/10.1113\/jphysiol.1966.sp007912","journal-title":"J Physiol"},{"key":"9713_CR57","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ajo.2017.09.030","volume":"184","author":"JC Wang","year":"2017","unstructured":"Wang JC, Lains I, Providencia J, Armstrong GW, Santos AR, Gil P, Gil J, Talcott KE, Marques JH, Figueira J, Vavvas DG, Kim IK, Miller JW, Husain D, Silva R, Miller JB (2017) Diabetic choroidopathy: choroidal vascular density and volume in diabetic retinopathy with swept-source optical coherence tomography. Am J Ophthalmol 184:75\u201383. https:\/\/doi.org\/10.1016\/j.ajo.2017.09.030","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"9713_CR58","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10439-006-9238-x","volume":"35","author":"F Mac Gabhann","year":"2007","unstructured":"Mac Gabhann F, Demetriades AM, Deering T, Packer JD, Shah SM, Duh E, Campochiaro PA, Popel AS (2007) Protein transport to choroid and retina following periocular injection: theoretical and experimental study. Ann Biomed Eng 35(4):615\u2013630. https:\/\/doi.org\/10.1007\/s10439-006-9238-x","journal-title":"Ann Biomed Eng"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-020-09713-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-020-09713-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-020-09713-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T23:51:01Z","timestamp":1630540261000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-020-09713-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9713"],"URL":"https:\/\/doi.org\/10.1007\/s10928-020-09713-0","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,2]]},"assertion":[{"value":"30 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}